logo-loader
viewBerkeley Group

Vistry upgraded by Citi as analysts “continue to see value” in UK housebuilders, but Barratt knocked down to ‘neutral’

Analysts at the bank said the spring selling season was likely to be a “key catalyst for the sector” while improving buyer interest is expected to support volume growth

Berkeley Group - Vistry upgraded by Citi as analysts “continue to see value” in UK housebuilders, but Barratt knocked down to ‘neutral’

Vistry Group PLC (LON:VTY), previously known as Bovis Homes, has been upgraded to ‘buy’ from ‘neutral’ by analysts at Citi, who said there is still value among the UK’s housebuilders despite a strong sector performance in 2019.

“We believe sector net assets are poised to grow [circa] +17% on an annualised basis…over the next three years, supported by modest volume growth, improving margin outlook and strong cash generation”, the bank said in a note on Friday.

READ: Persimmon, Taylor Wimpey and Countryside top picks for Berenberg as housebuilders “open for business again” following December election

Analysts said the spring selling season was likely to be a “key catalyst for the sector” while improving buyer interest is expected to support volume growth further.

Citi said Persimmon PLC (LON:PSN), Redrow plc (LON:RDW) and Taylor Wimpey PLC (LON:TW.) were its top picks for the sector, it downgraded Barratt Developments PLC (LON:BDEV) to ‘neutral’ from ‘buy’ and stayed neutral on Berkeley Group Holdings PLC (LON:BKG).

READ: Tory election victory to provide boost for housebuilders, says Canaccord, except McCarthy & Stone

Persimmon is the housebuilder attracted most positivity among analysts, with both Canaccord Genuity and Berenberg also listing the firm among their top picks in sector notes this week.

The positive outlook for the sector has been mostly attributed to the Conservative victory in last month’s election, which many say has restored certainty and attract more investment into the UK property market.

Quick facts: Berkeley Group

Price: 3615 GBX

LSE:BKG
Market: LSE
Market Cap: £4.54 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn Get US FDA approval to move to FastTrack to Phase 2...

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to discuss the company getting U.S. FDA  clearance to start a Phase 2 trial with leronlimab to treat COVID-19 patients with mild to moderate indications.  Pourhassan telling Proactive why they have been...

11 hours, 43 minutes ago

2 min read